Press Releases

AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 5, 2023-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 7,500 restricted stock units (RSUs) to one new

Jan 05, 2023



Investors & Media Sign up for
Email Alerts

We’ll keep you connected to the latest news about AVROBIO’s research and pipeline.